Literature DB >> 15931391

Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production.

Andre Bafica1, Charles A Scanga, Charles Serhan, Fabiana Machado, Sandy White, Alan Sher, Julio Aliberti.   

Abstract

Th1 type cytokine responses are critical in the control of Mycobacterium tuberculosis infection. Recent findings indicate that 5-lipoxygenase-dependent (5-LO-dependent) lipoxins regulate host IL-12 production in vivo. Here, we establish lipoxins as key chemical mediators in resistance to M. tuberculosis infection. High levels of lipoxin A4 (LXA4) were detected in sera from infected WT but not infected 5-LO-deficient mice. Moreover, lungs from M. tuberculosis-infected 5-lo-/- animals showed increased IL-12, IFN-gamma, and NO synthase 2 (NOS2) mRNA levels compared with the same tissues in WT mice. Similarly, splenocyte recall responses were enhanced in mycobacteria-infected 5-lo-/- versus WT mice. Importantly, bacterial burdens in 5-lo-/- lungs were significantly lower than those from WT mice, and this enhancement in the resistance of the 5-lo-/- animals to M. tuberculosis was completely prevented by administration of a stable LXA4 analog. Together our results demonstrate that lipoxins negatively regulate protective Th1 responses against mycobacterial infection in vivo and suggest that the inhibition of lipoxin biosynthesis could serve as a strategy for enhancing host resistance to M. tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15931391      PMCID: PMC1136995          DOI: 10.1172/JCI23949

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection.

Authors:  E Jouanguy; F Altare; S Lamhamedi; P Revy; J F Emile; M Newport; M Levin; S Blanche; E Seboun; A Fischer; J L Casanova
Journal:  N Engl J Med       Date:  1996-12-26       Impact factor: 91.245

2.  Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients.

Authors:  R de Jong; F Altare; I A Haagen; D G Elferink; T Boer; P J van Breda Vriesman; P J Kabel; J M Draaisma; J T van Dissel; F P Kroon; J L Casanova; T H Ottenhoff
Journal:  Science       Date:  1998-05-29       Impact factor: 47.728

3.  Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency.

Authors:  F Altare; A Durandy; D Lammas; J F Emile; S Lamhamedi; F Le Deist; P Drysdale; E Jouanguy; R Döffinger; F Bernaudin; O Jeppsson; J A Gollob; E Meinl; A W Segal; A Fischer; D Kumararatne; J L Casanova
Journal:  Science       Date:  1998-05-29       Impact factor: 47.728

4.  Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group.

Authors:  L M DuBuske; J Grossman; L M Dubé; L J Swanson; J F Lancaster
Journal:  Am J Manag Care       Date:  1997-04       Impact factor: 2.229

5.  Identification of nitric oxide synthase as a protective locus against tuberculosis.

Authors:  J D MacMicking; R J North; R LaCourse; J S Mudgett; S K Shah; C F Nathan
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

6.  A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group.

Authors:  H J Schwartz; T Petty; L M Dubé; L J Swanson; J F Lancaster
Journal:  Arch Intern Med       Date:  1998-01-26

7.  The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection.

Authors:  A M Cooper; A D Roberts; E R Rhoades; J E Callahan; D M Getzy; I M Orme
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

8.  Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group.

Authors:  E Israel; J Cohn; L Dubé; J M Drazen
Journal:  JAMA       Date:  1996-03-27       Impact factor: 56.272

9.  IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection.

Authors:  J L Flynn; M M Goldstein; K J Triebold; J Sypek; S Wolf; B R Bloom
Journal:  J Immunol       Date:  1995-09-01       Impact factor: 5.422

10.  Action of novel eicosanoids lipoxin A and B on human natural killer cell cytotoxicity: effects on intracellular cAMP and target cell binding.

Authors:  U Ramstedt; J Ng; H Wigzell; C N Serhan; B Samuelsson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

View more
  109 in total

1.  Building capacity for advances in tuberculosis research; proceedings of the third RePORT international meeting.

Authors:  Yuri F van der Heijden; Fareed Abdullah; Bruno B Andrade; Jason R Andrews; Devasahayam J Christopher; Julio Croda; Heather Ewing; David W Haas; Mark Hatherill; C Robert Horsburgh; Vidya Mave; Helder I Nakaya; Valeria Rolla; Sudha Srinivasan; Retna Indah Sugiyono; Cesar Ugarte-Gil; Carol Hamilton
Journal:  Tuberculosis (Edinb)       Date:  2018-10-01       Impact factor: 3.131

2.  The specialized proresolving mediator 17-HDHA enhances the antibody-mediated immune response against influenza virus: a new class of adjuvant?

Authors:  Sesquile Ramon; Steven F Baker; Julie M Sahler; Nina Kim; Eric A Feldsott; Charles N Serhan; Luis Martínez-Sobrido; David J Topham; Richard P Phipps
Journal:  J Immunol       Date:  2014-11-12       Impact factor: 5.422

Review 3.  Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not?

Authors:  Charles N Serhan
Journal:  Am J Pathol       Date:  2010-09-02       Impact factor: 4.307

4.  Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections.

Authors:  David M Tobin; Francisco J Roca; Sungwhan F Oh; Ross McFarland; Thad W Vickery; John P Ray; Dennis C Ko; Yuxia Zou; Nguyen D Bang; Tran T H Chau; Jay C Vary; Thomas R Hawn; Sarah J Dunstan; Jeremy J Farrar; Guy E Thwaites; Mary-Claire King; Charles N Serhan; Lalita Ramakrishnan
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

5.  Lethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse model of infection.

Authors:  Cristian Cilloniz; Mary J Pantin-Jackwood; Chester Ni; Alan G Goodman; Xinxia Peng; Sean C Proll; Victoria S Carter; Elizabeth R Rosenzweig; Kristy J Szretter; Jacqueline M Katz; Marcus J Korth; David E Swayne; Terrence M Tumpey; Michael G Katze
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

6.  Changes in inflammatory protein and lipid mediator profiles persist after antitubercular treatment of pulmonary and extrapulmonary tuberculosis: A prospective cohort study.

Authors:  Caian L Vinhaes; Deivide Oliveira-de-Souza; Paulo S Silveira-Mattos; Betania Nogueira; Ruiru Shi; Wang Wei; Xing Yuan; Guolong Zhang; Ying Cai; Clifton E Barry; Laura E Via; Kiyoshi F Fukutani; Bruno B Andrade; Katrin D Mayer-Barber
Journal:  Cytokine       Date:  2019-06-18       Impact factor: 3.861

Review 7.  Endogenous lipid mediators in the resolution of airway inflammation.

Authors:  O Haworth; B D Levy
Journal:  Eur Respir J       Date:  2007-11       Impact factor: 16.671

Review 8.  Interleukin-12 and tuberculosis: an old story revisited.

Authors:  Andrea M Cooper; Alejandra Solache; Shabaana A Khader
Journal:  Curr Opin Immunol       Date:  2007-08-16       Impact factor: 7.486

Review 9.  Host-directed therapeutics for tuberculosis: can we harness the host?

Authors:  Thomas R Hawn; Alastair I Matheson; Stephen N Maley; Omar Vandal
Journal:  Microbiol Mol Biol Rev       Date:  2013-12       Impact factor: 11.056

10.  5-Lipoxygenase activity increases susceptibility to experimental Paracoccidioides brasiliensis infection.

Authors:  Fabrine Sales Massafera Tristão; Fernanda Agostini Rocha; Ana Paula Moreira; Fernando Queiroz Cunha; Marcos Antonio Rossi; João Santana Silva
Journal:  Infect Immun       Date:  2013-02-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.